UNSPSC 51372111: Acetyldihydrocodeine hydrochloride

This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C20H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SGY1T84P34, chemically known as 7,8-dihydrocodeine acetate but more generally known as acetyldihydrocodeine, which bears US NIH Compound Identifier 5463874. European Medicines Agency schedules Acetyldihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12719MIG.

UNSPSC 51372111 Acetyldihydrocodeine hydrochloride is a Commodity code that in practice captures state and local procurement of pharmaceutical products, though the recent opportunities tagged to this code show minimal alignment with the specific opioid named in the code's title. The state and local bodies soliciting under or near this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Recent activity reflects broader pharmaceutical procurement across generic drugs, over-the-counter products, and opioid-antagonist medications such as naloxone, rather than acetyldihydrocodeine hydrochloride specifically. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon.

Geographic activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota and Oregon through MMCAP), with the Texas and Minnesota procurements representing statewide or multistate scope. The Seminole County naloxone solicitation, due July 26, 2026 (note: the summary contains conflicting dates; the most recent deadline stated is July 26, 2026), requires electronic bid submission, drug-free workplace and E-Verify certification, and includes a three-month probationary period with optional two-year renewal. The Minnesota MMCAP RFP, due March 26, 2026, requires vendors to supply through three authorized wholesalers, comply with cGMP and DSCSA, maintain insurance coverage including $5 million commercial general liability, and accept a 3 percent administrative fee on all purchases; awards are structured as sole, dual, or multi-awards based on therapeutic and patient-safety considerations. No recent opportunities show active solicitation specifically for acetyldihydrocodeine hydrochloride; the code's current activity reflects general pharmaceutical distribution infrastructure rather than the named substance.